SEC Form 4Coverage since Jul 1, 2026
$ORMP insider trading
Over the last 12 months, Oramed Pharmaceuticals insiders reported no purchases and 2 sales totaling $942K across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $942K 2 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $ORMP · 12Mvia TradingView
Top insiders · 12m
Gabay AvrahamChief Financial Officer1× · $331K
Hexter JoshuaCOO & CBO1× · $611K
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Hexter JoshuaCOO & CBO · O | ▼ Sale | 137,000 | $4.46 | $611K | -11.8% | plan |
| Jul 1, 2026 | Gabay AvrahamChief Financial Officer · O | ▼ Sale | 73,360 | $4.51 | $331K | -9.8% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ORMP feed.